ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Nivolumab

Also written as “nivolumab”, “ONO-4538” and “BMS-936558 (MDX-1106)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Melanoma · Carcinoma, Renal Cell · Carcinoma, Hepatocellular · Colorectal Neoplasms, led by 8 companies.

Drug pageNivolumab: every studyMany companies study it; this page follows only the 145 they lead. All 1,032 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Nov 2, 2015145 company-led studies, 14 open or runningNext primary completion: Feb 5, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb12410 open or runningphase 4since Nov 2, 2015Feb 27, 2007Feb 5, 2027phase 2 · NCT06946797
Ono Pharmaceuticalits history only144 open or runningphase 3since Oct 9, 2014Jan 26, 2009Dec 31, 2027phase 2 · NCT04566380
Pfizerits history only20 open or runningphase 2since Oct 7, 2015Oct 7, 2015none ahead
Ella Therapeuticsits history only10 open or runningphase 2since Aug 13, 2020Aug 13, 2020none ahead
ExcellaBioits history only10 open or runningphase 2since Oct 20, 2017Oct 20, 2017none ahead
Nilogen Oncosystemsits history only10 open or runningearly phase 1since Dec 3, 2017Dec 3, 2017none ahead
Rampart Healthits history only10 open or runningphase 2since Aug 9, 2019Aug 9, 2019none ahead
USWM CTits history only10 open or runningphase 2since Oct 26, 2022Oct 26, 2022none ahead

Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Halozyme Therapeutics, Medarex, Parexel, Astellas Pharma, Akamis Bio, Hoffmann-La Roche, Nektar Therapeutics, Eli Lilly, AbbVie and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Sep 14, 2016.

  1. Mar 16, 2020Phase 1 study in NeoplasmsNCT04311710 · 21 enrolled · United States, Italy, New Zealand
  2. Apr 7, 2020Phase 3 study in Liver NeoplasmsNCT04340193 · 26 enrolled · United States, Australia, Austria and more
  3. Jul 30, 2020Phase 2 study in MelanomaNCT04495010 · United States, Australia, Austria and more
  4. Aug 13, 2020Phase 4 study in Kidney NeoplasmsNCT04513522 · 101 enrolled · India
  5. Sep 24, 2020Phase 2 study in Carcinoma, HepatocellularNCT04567615 · 266 enrolled · Argentina, Brazil, Chile and more
  6. Nov 18, 2021Phase 2 study in Mesothelioma, MalignantNCT05136677 · 102 enrolled · China
  7. Feb 15, 2022Phase 2 study in Lymphoma, Non-HodgkinNCT05255601 · 5 enrolled · United States, Australia, France and more
  8. Aug 9, 2022Phase 2 study in MelanomaNCT05496192 · Germany, Spain
  9. Aug 10, 2022Phase 1 study in Advanced Solid TumorsNCT05498480 · 6 enrolled · China
  10. Nov 15, 2022Phase 3 study in MelanomaNCT05625399 · 579 enrolled · United States, Australia, Austria and more
  11. Oct 20, 2023Phase 2 study in MelanomaNCT06101134 · 100 enrolled · United States, Chile, Greece and more
  12. Aug 16, 2024Phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386 · 1,000 planned · United States, Argentina, Australia and more
  13. Apr 25, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06946797 · 76 enrolled · United States, Brazil, Chile and more
  14. Mar 5, 2026Phase 4 study in MelanomaNCT07459543 · 40 planned · India

Ahead

  1. Feb 5, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT06946797
  2. May 26, 2029Primary completion: phase 4 study in MelanomaNCT07459543
  3. Aug 25, 2029Primary completion: phase 2 study in NeoplasmsNCT03899155
  4. Jul 30, 2030Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT06561386

TargetBeta

PDCD1 →read by rule
“Programmed cell death protein 1 inhibitor”ChEMBL 37, by rule

Other programs on PDCD1

ProgramCompanyFurthest phaseStudies
ivonescimabruleAkesophase 348
rilvegostomigAstraZenecaphase 324
Iparomlimab/TuvonralimabruleQilu Pharmaceuticalphase 322
volrustomigAstraZenecaphase 319
tivunatamigPfizerphase 315
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
pucotenlimabruletaizhou-hanzhong-biomedical-co-ltdphase 315
enlonstobartruleCSPC Pharmaceutical Groupphase 315
ezabenlimabBoehringer Ingelheimphase 313
Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363ruleInnovent Biologicsphase 310
rulonilimabruleLunan Pharmaceutical Groupphase 39
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

The newest 60 of 124 Bristol-Myers Squibb leads. Each opens its study page. Every study on its drug page →

StudyPhaseStatusPrimary completionSize
NCT07459543Melanoma · India4Not yet recruitingMay 26, 202940
NCT06946797Carcinoma, Non-Small-Cell Lung · United States, Brazil, Chile and more2Active, not recruitingFeb 5, 202776
NCT06561386Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3RecruitingJul 30, 20301,000
NCT06101134Melanoma · United States, Chile, Greece and more2Active, not recruitingApr 10, 2025100
NCT05625399Melanoma · United States, Australia, Austria and more3Active, not recruitingAug 4, 2025579
NCT05498480Advanced Solid Tumors · China1CompletedJan 18, 20246
NCT05496192Melanoma · Germany, Spain2WithdrawnJun 24, 20240
NCT05255601Lymphoma, Non-Hodgkin · United States, Australia, France and more2TerminatedDec 3, 20255
NCT05136677Mesothelioma, Malignant · China2CompletedNov 12, 2025102
NCT04567615Carcinoma, Hepatocellular · Argentina, Brazil, Chile and more2CompletedAug 31, 2023266
NCT04513522Kidney Neoplasms · India4CompletedJan 4, 2024101
NCT04495010Melanoma · United States, Australia, Austria and more2WithdrawnFeb 28, 20240
NCT04340193Liver Neoplasms · United States, Australia, Austria and more3CompletedDec 12, 202326
NCT04311710Neoplasms · United States, Italy, New Zealand1TerminatedJan 14, 202121
NCT04209114Urinary Bladder Neoplasms · United States, Argentina, Australia and more3CompletedJun 7, 2023114
NCT04151563Carcinoma · United States, Argentina, Belgium and more2WithdrawnDec 17, 20230
NCT04149574Urinary Bladder Neoplasms · United States, Argentina, Australia and more3TerminatedOct 31, 202313
NCT04109066Breast Neoplasms · United States, Argentina, Australia and more3CompletedJan 16, 2023521
NCT04100018Prostatic Neoplasms · United States, Argentina, Australia and more3CompletedJun 1, 20231,030
NCT04099251Melanoma · United States, Australia, Austria and more3Active, not recruitingJun 28, 2022790
NCT04088500Carcinoma, Renal Cell · United States, Canada2TerminatedNov 15, 20215
NCT04075604Breast Neoplasms · United States, Australia, Belgium and more2CompletedJul 27, 202123
NCT04039607Carcinoma, Hepatocellular · United States, Argentina, Australia and more3CompletedJul 9, 2026732
NCT04026412Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedMar 22, 2024925
NCT04025879Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3Active, not recruitingJul 26, 2023461
NCT04008030Colorectal Neoplasms · United States, Argentina, Australia and more3Active, not recruitingAug 28, 2024839
NCT03980314Melanoma · United States, Argentina, Australia and more1CompletedMar 4, 2021261
NCT03899155Neoplasms · United States, Argentina, Australia and more2RecruitingAug 25, 20291,500
NCT03770299Carcinoma, Non-Small-Cell Lung2WithdrawnMar 14, 20230
NCT03704077Stomach Neoplasms · United States, Argentina, Australia and more2WithdrawnFeb 27, 20220
NCT03668119Pan Tumor · United States, Argentina, Australia and more2CompletedMay 3, 2022212
NCT03661320Urinary Bladder Neoplasms · United States, Argentina, Australia and more3CompletedFeb 16, 2026855
NCT03656718Neoplasms by Site · United States, Argentina, Brazil and more2CompletedSep 7, 2022139
NCT03519256Urinary Bladder Neoplasms · United States, Argentina, Australia and more2TerminatedAug 22, 2022142
NCT03444766Carcinoma, Non-Small-Cell Lung · India4CompletedJul 17, 2019100
NCT03414983Colorectal Neoplasms · United States, Canada, Japan and more3CompletedFeb 1, 2021196
NCT03383458Carcinoma, Hepatocellular · United States, Argentina, Australia and more3Active, not recruitingMay 27, 2026545
NCT03377361Colorectal Neoplasms · United States, Argentina, Australia and more2CompletedNov 4, 2024325
NCT03349710Squamous Cell Carcinoma of Head and Neck · United States, France, Italy and more3CompletedOct 14, 201974
NCT03338790Prostatic Neoplasms · United States, Argentina, Australia and more2CompletedJan 13, 2021292
NCT03215706Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more3CompletedAug 16, 2019719
NCT03195491Lung Neoplasms · China, Thailand3CompletedJun 8, 2021400
NCT03195478Solid Tumor · China2CompletedJan 5, 202437
NCT03143153Various Advanced Cancer · United States, Argentina, Australia and more3CompletedJan 18, 2021970
NCT03141177Carcinoma, Renal Cell · United States, Argentina, Australia and more3CompletedFeb 12, 2020701
NCT03138512Carcinoma, Renal Cell · United States, Argentina, Australia and more3CompletedSep 28, 20231,641
NCT03138499Hodgkin Disease · United States, Japan, Puerto Rico3TerminatedFeb 22, 202123
NCT03130959Various Advanced Cancer · United States, Australia, Brazil and more2CompletedMar 10, 2020166
NCT03098550Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more2CompletedJul 6, 2020105
NCT03090737Carcinoma, Non-Small-Cell Lung · United States, Canada, Japan and more2CompletedFeb 16, 2021129
NCT03048136Carcinoma, Non-Small-Cell Lung · United States, Argentina, Canada and more3WithdrawnSep 29, 20190
NCT03036098Urothelial Cancer · United States, Argentina, Australia and more3CompletedAug 30, 20241,314
NCT03029780Carcinoma, Renal Cell · United States, Australia, Chile2CompletedNov 27, 2017104
NCT03001882Carcinoma, Non-Small-Cell Lung · United States, Belgium, France and more2CompletedFeb 17, 2022230
NCT02998528Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more3CompletedSep 8, 2021505
NCT02982954Carcinoma, Renal Cell · United States4CompletedMay 11, 2020211
NCT02985957Prostatic Neoplasms · United States, Australia, Austria and more2CompletedApr 5, 2022351
NCT02960854Sepsis · United States1CompletedJan 5, 201838
NCT02927769Hodgkin Disease · United States, Canada, Czechia and more2CompletedMay 28, 202472
NCT02905266Melanoma · Australia, France, Italy and more3CompletedOct 23, 2017106

How it is read

Names in the registry

  • “Nivolumab”, 115 entries
  • “nivolumab”, 18 entries
  • “ONO-4538”, 13 entries
  • “BMS-936558 (MDX-1106)”, 5 entries
  • “Nivolumab + Relatlimab”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.